SCHEMBL19626307

SCHEMBL19626307

CCn1cc(-c2cn(COCC[Si](C)(C)C)nc2Cl)c2cc(C#CC(C)(C)O)c(F)cc21

nearest known ligand 0.48

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAP3K14 Q99558 12/20 0.48
CHUK O15111 6/20 0.37
DGAT1 O75907 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19626298 0.90 MAP3K14 (0.56) MAP3K14CHUK
SCHEMBL19629497 0.89 MAP3K14 (0.47) MAP3K14CHUK
SCHEMBL19626303 0.88 MAP3K14 (0.47) MAP3K14CHUK
SCHEMBL19626305 0.87 MAP3K14 (0.37) MAP3K14CHUK
SCHEMBL19626299 0.84 MAP3K14 (0.47) MAP3K14CHUK
SCHEMBL16608302 0.84 CHUK (0.56) MAP3K14CHUK
SCHEMBL19626301 0.84 MAP3K14 (0.61) MAP3K14CHUK
SCHEMBL19626247 0.83 MAP3K14 (0.52) MAP3K14CHUK
SCHEMBL19626297 0.82 MAP3K14 (0.59) MAP3K14CHUK
SCHEMBL19626258 0.81 DGAT1 (0.34) DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9981962-B2 Pyrazole derivatives as NIK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2018-05-29 US disclosed
US-9981962-B2 Pyrazole derivatives as NIK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2018-05-29 US disclosed
US-20170334900-A1 NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS ARGENTA DISCOVERY 2009 LIMITED (GB) 2017-11-23 US disclosed
US-20170334900-A1 NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS ARGENTA DISCOVERY 2009 LIMITED (GB) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334900-A1 NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS MAP3K14, MAP3K15, MAP3K21 MAP3K14 1/4885CHUK 32/4885DGAT1 2063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.